Leo Cancer Care has raised $65 million in Series D financing to scale its integrated upright cancer care platform, which is designed to image and treat patients in a seated position rather than the conventional lying-down setup. The oversubscribed round supports manufacturing scale-up, commercial deployment and continued development across upright proton therapy, photon therapy and
Sino Biopharmaceutical Limited has secured two respiratory medicine transactions involving AstraZeneca PLC and GSK plc, strengthening both its out-licensing and China commercialization strategy. Its subsidiary Chia Tai Tianqing Pharmaceutical Group granted AstraZeneca exclusive rights outside China to develop, manufacture and commercialize TQC3721, an investigational PDE3/4 inhibitor for chronic respiratory disease, while separately obtaining mainland China
Seres Therapeutics Inc. (Nasdaq: MCRB) has reported early clinical data for SER-155 in immune checkpoint inhibitor-related enterocolitis, a gastrointestinal immune-related adverse event that can interrupt cancer immunotherapy. The investigator-sponsored study evaluated the live biotherapeutic in 15 patients with moderate to severe disease and showed an immunosuppressive free clinical response in 80 percent of participants at
Conavi Medical Corp. has announced a peer-reviewed case publication highlighting the use of its hybrid intravascular ultrasound and optical coherence tomography imaging system in a complex coronary intervention involving a patient with impaired renal function. The publication follows U.S. Food and Drug Administration 510(k) clearance for the Canadian medical device developer’s next-generation hybrid IVUS-OCT imaging
UroGen Pharma Ltd. (Nasdaq: URGN) has received U.S. Food and Drug Administration clearance of its Investigational New Drug application for UGN-501, an investigational next-generation oncolytic virus for non-muscle invasive bladder cancer. The clearance enables the urothelial cancer-focused biotechnology company to begin a planned Phase 1 trial of local intravesical administration, with patient enrollment expected to
Endogenex has completed enrollment in the ReCET Clinical Study, a pivotal evaluation of the Endogenex System in adults with type 2 diabetes whose blood glucose levels remain inadequately controlled on non-insulin glucose-lowering medications. The study has enrolled 350 patients across approximately 40 sites in the United States and Australia, moving the clinical-stage medical device developer
MAIA Biotechnology has reported positive initial efficacy data from Part C of the Phase 2 THIO-101 expansion trial evaluating ateganosine followed by cemiplimab in third-line advanced non-small cell lung cancer. The clinical-stage oncology drug developer said the regimen produced a 90.5 percent interim disease control rate among efficacy-evaluable patients, placing its telomere-targeting strategy back in
iHealthScreen Inc. has received U.S. Food and Drug Administration 510(k) clearance for iPredict-DR, an AI-powered Software as a Medical Device for automated diabetic retinopathy screening. The retinal imaging software detects more than mild diabetic retinopathy in adults with diabetes who have not previously been diagnosed with the condition, placing the healthcare AI developer into a
OKYO Pharma’s urcosimod moves toward Phase 3 as the biotech targets neuropathic corneal pain, a severe ocular condition without approved therapy.
Royal Philips’ Alturion ultrasound launch targets AI-powered imaging workflows as hospitals face rising scan volumes and staffing pressure.